Merck MS Drug Fails to Meet Target of Late-Stage Trials
06 Dezembro 2023 - 3:37AM
Dow Jones News
By David Sachs
Merck's multiple sclerosis drug evobrutinib didn't meet a key
goal in late-stage trials.
The German pharmaceutical company's phase 3 clinical trials for
the drug did not achieve their primary target of reducing
annualized relapse rates in people with relapsing multiple
sclerosis, it said late Tuesday. The drugmaker was aiming to match
the rate of Aubagio, an oral drug for the disease owned by
Sanofi.
"While we are very disappointed with the results, we continue to
advance our strategy in healthcare with a focus on progressing our
marketed portfolio and internal pipeline, complemented by external
innovation, with the aim of bringing more medicines to patients,
faster," said Danny Bar-Zohar, head of research and development at
Merck.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 06, 2023 01:22 ET (06:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Merck KGaA (PK) (USOTC:MKKGY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Merck KGaA (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Merck KGaA (PK)